A 12-year-old girl with Sly disease (mucopolysaccharidosis VII; ␤-glucuronidase deficiency), who is homozygous for the A619V mutation, had a successful allogeneic BMT, donored by an HLA-identical unrelated female to replace the deficient enzyme. Within 5 months after BMT, the enzyme activity of the recipient's lymphocytes increased to normal range. No signs of acute or chronic GVHD were observed. For the successive 31 months post-BMT, ␤-glucuronidase activity in her lymphocytes was maintained at almost normal levels and excretion of glycosaminoglycans in the urine was greatly diminished. Ultrastructural findings demonstrated no abnormal vacuoles and inclusion bodies in the cytoplasm of her rectal mucosal cells. Coincident with the restoration of the enzyme activity, clinical improvement was dramatic. Especially notable were improvements in motor function. The patient was able to walk alone for a long time without aid, and she even became able to ride a bicycle and take a bath. In addition, recurrent infections of the upper respiratory tract and the middle ears decreased in frequency and severity, and dyspnea on exertion, severe snoring and vertigo have substantially improved. Thus, allogeneic BMT in this patient produced a better quality of life and provided a more promising outlook.
patient described here. Since then, about 40 cases have been reported with an impressively wide spectrum of clinical manifestations. cDNA cloning and sequencing from several species has been achieved. [2] [3] [4] Tomatsu et al 5, 6 identified the first causative mutation (Ala619Val) in a 6-year-old Japanese girl. Homozygosity for this point mutation was also detected in an unrelated 24-year-old Japanese male with similar clinical features in his first 8 years of life.
BMT has been proposed as a treatment for inherited lysosomal storage diseases, 7 both to correct by replacement the bone marrow-derived cells in the recipient, and also to correct other cells which take up enzyme secreted by the bone marrow-derived cells, especially macrophages. The origin of tissue macrophages, such as those of liver and lung, is the bone marrow. 8 Birkenmeir et al 9 showed that the life span of adult MPS VII mice treated with BMT increased approximately three-fold, approaching that observed in normal mice, suggesting that BMT also has a place in the therapeutic regimen of human MPS VII patients.
In this report, we describe the biochemical and clinical findings 31 months after successful allogeneic BMT in a female MPS VII patient with a defined genotype, and compare them with findings in an unrelated MPS VII patient with the same genotype.
Patients and methods

Case report
The patient was the product of a 38-week, uncomplicated first pregnancy of related parents (first cousins). Her birth weight was 2800 g. She had coarse facial features, hepatosplenomegaly, umbilical herniation, peripheral pulmonary stenosis, ventricular septal defect, severe neonatal jaundice and abnormal peripheral leukocytes with striking coarse metachromatic granules. The diagnosis was established at the age of 1 month by the demonstration of a pronounced increase in the excretion of the urinary dermatan sulphate and chondroitin-4/6-sulphate and a deficiency of ␤-glucuronidase activity in the leukocytes. At 6 years age, Tomatsu et al 5, 6 identified the mutation in her ␤-glucuronidase cDNA as a C to T transition, producing the Ala619Val alteration. Her parents and younger brother were confirmed to be heterozygotes enzymatically and genetically. She suffered from recurrent acute otitis media since she was several months old, and mild deafness was first recognized when she was 5 years old.
Although her development delay had not been noticed until 3 years of age, mental retardation progressed gradually after that. Her general bone deformity (a lumbar gibbus, bilateral femoral caput hypoplasia) worsened yearly, and she became wheel-chair bound at 10 years of age because of gait disturbance, severe pain in the femoral head, and shortness of breath. The patient's grasp became weaker until she could not lift up her bag. Recurrent infections of the upper respiratory tract and middle ears occurred. At the parents' request and in order to replace the missing enzyme and to reverse her progressive neurologic and somatic involvement, a BMT was considered. No family HLAidentical donor was available, so the Japan Bone Marrow Transplantation Registry was searched for an appropriate donor. HLA typing identified an unrelated female donor whose HLA antigens matched those of the patient (see below). Mixed lymphocyte culture (MLC) test was negative.
Physical examination (5 months before BMT) (Table 1)
Her height was 141.5 cm (Ϫ1.4 s.d.), and weight was 47 kg (ϩ0.6 s.d.). Body mass index was 23.4. Her intelligence quotient (IQ; Wechsler intelligence scale for children, revised) was 50. Ultrasonic echocardiogram showed moderate aortic valve and mitral valve regurgitation. She had severe snoring and needed a wheel chair to move since she could not walk alone because of severe hip pain. MRI imaging of her brain showed brain atrophy and ventricular enlargement.
Bone marrow transplantation
She was 12 years old when she was admitted to the Japanese Red Cross Nagoya First Hospital for allogeneic BMT. She was isolated in a laminar air flow room and was given gut decontamination with polymyxin B, vancomycin hydrochloride and amphotericin B. On 27 October 1994, she received 3.18 ϫ 10 8 /kg bone marrow total nucleated cells from an unrelated female donor after conditioning with busulfan (4 mg/kg/day ϫ 4 days), cyclophosphamide (50 mg/kg/day ϫ 4 days) and rabbit anti-human thymocyte globulin (3.75 mg/kg/day ϫ 4 days; Pasteur Mérieux, Paris, France). She was identical with the bone marrow donor in blood type, HLA-A, B, DR, DQ, and DP on DNA typing. Mix lymphocyte culture (MLC) was negative between the patient and donor and short-term methotrexate and cyclosporin were given for the GVHD prophylaxis.
The dates of WBC 1 ϫ 10 9 /l, neutrophil 0.5 ϫ 10 9 /l, platelet 50 ϫ 10 9 /l and reticulocyte 1% were day 15, 15, 25 and 28, respectively. The last platelet transfusion was given on day 22. No signs of acute or chronic GVHD were observed but symptoms of congestive heart failure were noted from day 6. Catecholamines and diuretics were given to improve her cardiac function and congestive heart failure was resolved by day 55. She also had interstitial pneumonia caused by cytomegalovirus on day 37 for which ganciclovir was effective. On day 37, she developed acute otitis media for which tympanotomy was carried out. She was discharged from the hospital 128 days after transplantation. On day 123, her minor red blood cell antigens were found to be completely donor type.
Biochemical analysis
␤-Glucuronidase enzyme activity in lymphocytes and rectal mucosa were measured with the substrate 4-methylumbelliferyl-␤-d-glucuronide (Wako, Osaka, Japan). 10 Total mucopolysaccharides in the urine were precipitated with cetylpyridinium chloride and uronic acid was determined by the carbazol method of Bitter and Muir. 11 
Electron microscopy
Rectal mucosa from the patient was obtained before and after bone marrow transplantation using Crosby-Kuglar intestinal biopsy capsule. The tissues were fixed with 2.5% glutaraldehyde in Millonig's buffer (pH 7.4) for 1 h, postfixed in 1% OsO 1 for 1 h, embedded in Epon 812 (Nissin, Tokyo, Japan). The ultrathin sections were stained with uranyl acetate and lead salts, and examined with a Hitachi H-700 (Hitachi, Tokyo, Japan) electron microscope.
Clinical course of the untreated patient
Another patient had the same ␤-glucuronidase genotype as the index case but did not undergo BMT. This male began to walk without support at the age of 2 years. At the age of 4 years he underwent an operation for right inguinal herniation. He was noticed to have a limping gait from 5 years of age. X-ray examination of bones showed skeletal abnormalities. Abnormal granules were also observed in his leukocytes. His IQ was estimated to be 66 at the age of 14 years. His height was 125.2 cm (Ϫ5.5 s.d.). He was diagnosed as ␤-glucuronidase deficiency by enzyme assay at the age of 24 years. He died from a traffic accident while riding a bicycle at the age of 30 years. His motor function had remained fairly good except for a limping gait due to dislocation of the left hip joint and he was able to care for himself on a daily basis. There had been no signs and symptoms of progressive motor dysfunction, mental retardation or recurrent infections, and his condition was stable when he died.
Results
Biochemical results
Lymphocyte ␤-glucuronidase: As shown in Table 2 , the pre-transplant value for ␤-glucuronidase activity in the 
Uronic acid/creatinine:
The pre-transplant value for uronic acid/creatinine in the patient's urine was 44 mg/g (normal range: 6.4 Ϯ 2.4, n ϭ 10). After BMT, uronic acid/creatinine in her urine steadily decreased to 18, 16, and 14 mg/g by day 151, 271 and 398 after BMT, respect-ively (Table 3) . This was consistent with induced glycosaminoglycans (CAG) degradation.
Electron microscopic analyses
Plasma cells, macrophages, smooth muscle cells and fibroblasts of the patient's rectal mucosa contained distended lysosomal storage material before BMT (Figure 1a) . However, this disappeared after BMT (Figure 1b) . (Figure 1a and b show only plasma cells.)
Clinical progress 18 months after BMT (Table 1)
Her height was 141.5 cm (Ϫ2.8 s.d.) , and weight 41.3 kg (Ϫ1.1 s.d.) . Her body mass index decreased from 23.4 to 20.6. Her intelligence quotient (IQ) (Wechsler intelligence scale for children, revised) was 47, which was almost the same as pre-BMT. The post-BMT brain imaging by MRI scan was not significantly different from that seen pre-BMT. Ultrasonic echogram showed moderate aortic valve and mitral valve regurgitation. These abnormalities did not worsen after BMT. Cardiac evaluation by echocardiography and electrocardiography showed no change 12 months after transplantation and remained stable at 31 months. After BMT, she ceased to suffer from recurrent infections of upper respiratory tract and middle ears. Snoring and vertigo were also significantly diminished. Moreover, improvement in motor function has made it easy for her to take care for herself on a daily basis. She was able to walk short distances without assistance due to relief of the hip pain and absence of shortness of breath, although X-ray examinations of her vertebrae and hip joints were similar before and after BMT. She even learned to ride a bicycle and take a bath by herself.
We used the Multi-attribute Health Status Classification System which was devised by Feeny et al 12 to assess her quality of life (QOL) pre-and post-BMT. The levels were 3 or 4 pre-BMT, but post-BMT, these improved to 1 or 2 in all attributes except for fertility (Table 4) .
Discussion
BMT may be beneficial in the treatment of some storage diseases. [13] [14] [15] [16] [17] Animal studies suggest that BMT has a place in the treatment of MPS VII. Birkenmier et al 9 reported that in adult MPS VII mice, BMT resulted in a significantly increased life span which was similar to that observed for normal mice given the same therapy. However, a discour- Table 3 Ratios of uronic acid/creatinine before and after BMT aging finding was the minimal correction that occurred in the central nervous system and skeleton of adult MPS VII mice receiving BMT. Bastedo et al 18 concluded that BMT even in the newborn period did not improve the neurological function of the mutant gus m p s /gus m p s mice, possibly because the neurological damage was irreversible.
In our report, normal bone marrow was engrafted for 31 months in a 12-year-old patient with Sly disease. Five months after BMT, ␤-glucuronidase activity in the patient's lymphocytes increased to almost normal levels with a decrease in urinary excretion of glycosaminoglycans, and disappearance of abnormal vacuoles and inclusion bodies in the rectal mucosal cells. Continuing improvement was seen for the next 10 months, providing definite evidence that the donor bone marrow had completely engrafted in the recipient. In addition to biochemical improvement, her clinical course was better than pre-BMT, particularly in motor function (achievement of walking, riding and taking a bath alone), absence of shortage of breath while moving, recurrent infections and snoring.
Neurological damage was not reversed, as evidenced by the post-BMT IQ test compared with that taken pre-BMT. In this respect, the results resemble those in the MPS VII mouse experiments, and in BMT cases in other types of MPS. However, if the patient maintains this IQ for many years, it will suggest that BMT can prevent progressive brain damage or mental retardation.
The effect of BMT on the neurological components of this type of patient has been difficult to assess, both qualitatively and quantitatively. The principal difficulty comes from not knowing whether BMT patients with engraftment would have remained towards the mild end of the clinical spectrum without treatment. The extent of clinical heterogeneity seen in the MPS VII patients is particularly impressive, reflecting in part the allelic heterogeneity of ␤-glucuronidase mutations.
Efforts to correlate clinical phenotype with molecular mutations may allow better assessment of the benefit-torisk of BMT as has been the case in MPS I (Hurler syndrome). 19 Interestingly, another unrelated male Japanese patient (diagnosed as MPS VII at the age of 24) was also homozygous for the Ala619Val mutation. His clinical course up to 8 years of age was very similar to that of this patient. Namely, he was noted to have gait disturbance from the age of 5 years and was also shown to have skeletal abnormalities and moderate mental retardation. However, his symptoms were not so progressive over the next 20 years. Based on his clinical history, we expected the female patient presented here to have a good prognosis, needing only conservative therapy after 8 years of age. However, in contrast to our prediction based on her phenotype at 8 years of age, her symptoms worsened year by year with progressive motor dysfunction and mental retardation. Thus, even though BMT still carries a high risk of mortality and morbidity from GVHD and other complications, in accordance with her parents' desire, we decided to trans- Table 4 The Multi-attribute Health Status Classification of our patient plant this patient in an attempt to arrest the progression of her symptoms and restore her quality of life.
Patients with a genotype associated with a severe disease phenotype tend to develop pathologies within a relatively narrow clinical spectrum. However, there is more variability in mutations producing phenotypes toward the mild end of the clinical spectrum. Thus, clinical observation of the individual patient is as important as genotype in making a decision regarding the need for BMT. Although we can not yet conclude whether BMT in MPS VII patients is effective in producing neurological improvement, longterm evaluation of patients like this patient and accumulation of data from additional patients receiving BMT for MPS VII should clarify this issue. Overall, the favorable biochemical and clinical responses to allogeneic BMT reported here are quite promising. In addition, this approach need not be limited to donors and recipients as closely related as our patient and her unrelated donor. Umbilical cord blood from unrelated donors will greatly expand the opportunities for bone marrow replacement in lysosomal storage diseases such as MPS VII.
